Arecent study investigated the association between the types and duration of androgen deprivation therapy (ADT, or hormone therapy) and the risk of type 2 diabetes. Researchers used data from the Prostate Cancer database Sweden and compared diabetes risk in 34,031 men with prostate cancer on various types of ADT: anti-androgens (9,143 men), surgical removal of the testicles (3,014 men), or gonadotropin-releasing hormone agonists (21,874 men).
When compared to men without prostate cancer, men on gonadotropinreleasing hormone agonists and in the surgical testicle removal group had an increased risk of type 2 diabetes during the first 3 years of ADT. The risk decreased thereafter. There was no increased risk seen in men on antiandrogens. The authors concluded that men on ADT, even for a limited period of time such as with radiation therapy, had an increased risk of type 2 diabetes.
Int J Cancer. 2016 Dec 15;139(12):2698-2704. doi: 10.1002/ijc.30403. Epub 2016 Sep 19.